Every 8-K that Cantor Equity Partners Iv, Inc. (CEPF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CEPF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CEPF filings page.
Cantor Equity Partners IV, Inc. (symbol CEPF) appointed Dr. Mukesh Prasad to its board of directors effective August 25, 2026. He will serve as a Class I director and join both the audit committee and the compensation committee.
Dr. Prasad, age 55, is Founder and Co-Managing Partner of Innova Capital Partners and an Otolaryngologist at Weill Cornell Medical College, where he has served as Associate Professor of Clinical Otolaryngology and Head and Neck Surgery since 2002. He has prior board experience with related Cantor investment vehicles. For his board service at Cantor Equity Partners IV, Inc., he will receive $50,000 per year, paid quarterly. The company states there are no family relationships between Dr. Prasad and its directors or executive officers.
Cantor Equity Partners IV, Inc. announced that its board appointed Alan Riffkin as a Class II director effective February 10, 2026. On the same date, he also joined the company’s audit and compensation committees, taking on key oversight roles in financial reporting and executive pay.
The board approved annual compensation of $50,000 for Mr. Riffkin’s board service, to be paid quarterly. He brings extensive finance and real estate experience from senior roles at Lazard, Goldman Sachs, Citicorp, and his current leadership positions at AFR Capital Advisory LLC and AirWave Lease Insights.
Cantor Equity Partners IV, Inc. completed its initial public offering of 45,000,000 Class A ordinary shares at $10.00 per share, generating $450,000,000 in gross proceeds. The underwriters partially exercised their over-allotment option, accounting for 5,000,000 of these shares.
At the same time, the company sold 900,000 additional Class A ordinary shares in a private placement to its sponsor at $10.00 per share, raising another $9,000,000. A total of $450,000,000, or $10.00 per public share, from the IPO and private placement proceeds was deposited into a U.S.-based trust account, a common structure for special purpose acquisition vehicles. An audited balance sheet as of August 22, 2025 reflecting these proceeds is provided as an exhibit.